Application of predictive models in boosting power of Alzheimer's disease clinical trials: A post hoc analysis of phase 3 solanezumab trials
Abstract Background The ideal participants for Alzheimer's disease (AD) clinical trials would show cognitive decline in the absence of treatment (i.e., placebo arm) and would also respond to the therapeutic intervention. Objective To investigate if predictive models can be an effective tool for...
Saved in:
| Main Authors: | Ali Ezzati, Christos Davatzikos, David A. Wolk, Charles B. Hall, Christian Habeck, Richard B. Lipton |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Alzheimer’s & Dementia: Translational Research & Clinical Interventions |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/trc2.12223 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Lecanemab for mild Alzheimer disease – is there a way forward?
by: Rajesh R Tampi
Published: (2025-03-01) -
Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
by: Xiaojuan Li, et al.
Published: (2025-04-01) -
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01) -
Disease Modifying Monoclonal Antibodies and Symptomatic Pharmacological Treatment for Alzheimer’s Disease
by: Xiaoming Qi, et al.
Published: (2024-11-01) -
Alzheimer’s Disease in the Context of an Aging Society: Challenges and Future Directions
by: Aleksandra Boral, et al.
Published: (2025-07-01)